Demographic and clinical characteristics at start of therapeutic ART | ZDVm-experienced (n = 91) | ART-naïve (n = 1937) | p-value | |||
---|---|---|---|---|---|---|
Age (years), median (IQR) | 33 | (30–37) | 35 | (30–40) | 0.01 | |
Time since HIV diagnosis (years), median (IQR) | 5 | (4–9) | 4 | (2–7) | <0.001 | |
Pregnant, n (%) | 27 | (29.7) | 147 | (7.6) | <0.001 | |
Ethnicity, n (%) | Black | 67 | (73.6) | 1349 | (69.6) | 0.42 |
Non-black/not known | 24 | (26.4) | 588 | (30.3) | ||
Risk group, n (%) | Heterosexual sex | 89 | (97.8) | 1718 | (88.7) | 0.006 |
Other | 2 | (2.2) | 219 | (11.3) | ||
Year, n (%) | 2000-2002 | 13 | (14.3) | 375 | (19.4) | 0.40 |
2003-2005 | 32 | (35.1) | 589 | (30.4) | ||
2006-2009 | 46 | (50.6) | 973 | (50.2) | ||
ART regimen started, n (%) | ||||||
PI based (boosted and non-boosted) | 22 | (24.2) | 552 | (28.5) | 0.48 | |
NNRTI | 57 | (62.6) | 1192 | (61.5) | ||
NRTI/other | 12 | (13.2) | 193 | (10.0) | ||
Baseline CD4 count | Median (IQR), (cells/mm3) | 226 | (162–339) | 225 | (150–304) | 0.16 |
(n = 75, n = 1431) | CD4 <200 cells/mm3, n (%) | 29 | (38.7) | 584 | (40.8) | 0.71 |
CD4 <350 cells/mm3, n (%) | 57 | (76.0) | 1195 | (83.5) | 0.09 | |
Baseline viral load | Median (IQR), (log10 copies/ml) | 4.1 | (3.2-4.5) | 4.3 | (3.4-4.9) | 0.08 |
(n = 68, n = 1371) | ≤50 copies/ml, n (%) | 4 | (5.9) | 126 | (9.2) | 0.35 |
≤400 copies/ml, n (%) | 8 | (11.8) | 228 | (16.6) | 0.29 | |
≤10,000 copies/ml, n (%) | 28 | (41.2) | 535 | (39.0) | 0.72 | |
Hepatitis C co-infection, n (%) | 4 | (4.4) | 170 | (8.8) | 0.14 | |
Hepatitis B co-infection, n (%) | 1 | (1.1) | 55 | (2.8) | 0.32 | |
Previous AIDS event, n (%) | 7 | (7.7) | 279 | (14.4) | 0.07 |